8-K: INVO Fertility Acquires Family Beginnings Clinic Assets

INVO Fertility, Inc. has signed a definitive agreement to acquire the non-clinical assets of Family Beginnings, P.C., an Indiana-based fertility clinic, for $750,000.

Summary

• INVO Fertility, Inc., through its wholly owned subsidiary INVO Centers LLC, is acquiring the non-clinical assets of Family Beginnings, P.C., a fertility clinic in Indianapolis, Indiana.
• The total purchase price is $750,000, comprising $350,000 in cash (less a $150,000 holdback amount) and $400,000 in INVO's Series D Non-Voting Convertible Preferred Stock.
• The closing of the transaction is expected by February 27, 2026; if it occurs after January 31, 2026, the cash portion of the purchase price will increase by $10,000.
• Family Beginnings generated approximately $1.2 million in revenue and $0.2 million in net income for the trailing 12-month period ended September 30, 2025.
• Dr. James Donahue, the current owner and medical director of Family Beginnings, will continue to lead the clinic under a new three-year employment agreement with the New PC.
• The acquisition includes non-clinical assets such as receivables, inventory, equipment, goodwill, and intellectual property, while patient lists, contracts with payors, and health care permits are excluded.
• Dr. Donahue has agreed to a five-year non-compete and non-solicitation provision within a 50-mile radius of any New PC clinic location and generally for fertility practice in Indiana, with specific exclusions for certain activities.

Sentiment

Score: 7

Explanation: The acquisition is a positive strategic step for INVO, expanding its market presence and integrating a profitable clinic with a strong reputation. The retention of key management (Dr. Donahue) is also a significant positive. While the non-clinical asset acquisition structure adds complexity, it's a common practice in healthcare. The financial terms appear reasonable for the acquired revenue and net income. The preferred stock issuance is a non-dilutive way to finance part of the acquisition, though its non-voting nature might be less appealing to the seller. Overall, it's a solid, expected move for growth.

Positives

• The strategic acquisition expands INVO's footprint of fertility care centers across the United States, aligning with its mission to increase access to advanced fertility care.
• INVO is acquiring a respected clinic with a strong clinical reputation, an experienced team, and a shared commitment to patient-centered, cost-effective fertility solutions.
• Family Beginnings has a history of personalized care and strong success rates, having served thousands of patients across Indiana and surrounding states.
• The retention of Dr. James Donahue, the clinic's founder and medical director, for a minimum of three years ensures continuity of leadership and clinical expertise.
• The acquisition of a profitable clinic (generating $1.2 million in revenue and $0.2 million in net income TTM) is expected to contribute positively to INVO's financial performance.

Negatives

• The acquisition is limited to non-clinical assets, meaning INVO will need to establish new agreements for clinical services, patient lists, payor contracts, and health care permits through a separate PC Asset Purchase Agreement, Management Services Agreement, and Dr. Donahue's employment agreement.
• A $150,000 holdback amount from the cash payment introduces a contingency for the seller, subject to post-closing adjustments.
• The cash portion of the purchase price will increase by $10,000 if the closing occurs after January 31, 2026, potentially increasing the acquisition cost for INVO.
• A portion of the purchase price ($400,000) is paid in Series D Non-Voting Convertible Preferred Stock, which may be less liquid or desirable than cash or common stock for the seller.

Risks

• The closing is subject to the satisfaction or waiver of several conditions, including the execution of a PC asset purchase agreement, a management services agreement, an employment agreement for Dr. Donahue, and a new lease, any of which could delay or prevent the transaction.
• There is a risk that necessary third-party consents or waivers for assumed contracts may not be obtained, potentially impacting the seamless transfer of operations.
• The post-closing adjustment mechanism, based on various financial metrics, could result in the seller owing money back to the buyer, potentially reducing the effective purchase price.
• Integration risks are inherent in combining Family Beginnings' operations with INVO's existing structure, which could affect operational efficiency or expected synergies.
• The filing contains forward-looking statements that involve risks and uncertainties, including regulatory risks and the ability to achieve desired business, operational, and financial outcomes from the acquisition.
• Indemnification claims are subject to specific limitations and survival periods, and there is a risk of incurring Losses from pre-closing liabilities or breaches of representations and warranties.

Future Outlook

INVO Fertility expects the acquisition to expand its footprint of fertility care centers across the United States and increase access to advanced fertility care. The company anticipates integrating Family Beginnings' operations and growing the practice within the local market. The closing is subject to standard conditions and is expected by February 27, 2026.

Management Comments

• "We are pleased to move forward with this strategic acquisition, which aligns with our mission to increase access to advanced fertility care." Steve Shum, CEO of INVO.
• "Family Beginnings, under the leadership of James Donahue MD, brings a strong clinical reputation, an experienced team, and a shared commitment to patient-centered, cost-effective fertility solutions." Steve Shum, CEO of INVO.
• "We look forward to integrating its operations into INVO and to working closely with the Family Beginnings team to expand on the solid foundation they have built and further grow the practice within the local market." Steve Shum, CEO of INVO.

Industry Context

This acquisition reflects a broader trend in the healthcare industry, particularly in specialized medical fields like fertility, where larger entities seek to consolidate smaller, reputable practices to achieve economies of scale, expand geographic reach, and integrate proprietary technologies. INVO's strategy of acquiring profitable IVF clinics and establishing INVO Centers (utilizing its INVOcell device) positions it to compete by offering a range of ART treatments, including more affordable options like IVC, which could appeal to a wider patient demographic and address the high cost barrier often associated with fertility treatments.

Comparison to Industry Standards

• The acquisition of non-clinical assets while establishing new agreements for clinical services (PC Asset Purchase Agreement, Management Services Agreement, Employment Agreement) is a common structure in healthcare acquisitions, particularly to navigate corporate practice of medicine doctrines in various states.
• The purchase price of $750,000 for a clinic generating $1.2 million in revenue and $0.2 million in net income (TTM) suggests valuation multiples (e.g., ~0.6x revenue, ~3.75x net income) that appear reasonable for a small, profitable practice in the fertility sector, especially considering the non-clinical asset focus and the retention of key personnel. A direct assessment against global benchmarks is difficult without specific comparable company data.
• The inclusion of preferred stock as part of the consideration is also common in M&A, allowing the buyer to conserve cash and align the seller's interests with the buyer's long-term performance.

Management Changes

Legal Proceedings

• The filing mentions an existing Action brought by J.G., J.G., and M.G. against the Company (Family Beginnings) and the Seller (Dr. Donahue) as an Excluded Liability, meaning INVO is not assuming this liability.

Related Party Transactions

• The Seller, Dr. James Donahue, is the sole owner of Family Beginnings, P.C., and is selling its non-clinical assets to INVO's subsidiary.
• Dr. Donahue will be employed by the New PC (Fertility, P.A.) for a minimum of three years to continue providing fertility services for the Clinic.
• Dr. Donahue is subject to a five-year non-compete and non-solicitation agreement with the Buyer and New PC.

Stakeholder Impact

• Shareholders (INVO): Potential for increased revenue and market share through strategic expansion, but also exposure to integration risks and the issuance of preferred stock.
• Employees (Family Beginnings): Non-physician employees may be terminated by Family Beginnings, but Buyer may offer them employment, potentially leading to job continuity under new ownership. Dr. Donahue's employment is secured for at least three years.
• Customers/Patients (Family Beginnings): Expected continuity of fertility services under Dr. Donahue's leadership, with potential for expanded access to INVO's technologies like INVOcell.
• Creditors (Family Beginnings): Existing debts and liabilities (other than assumed liabilities) remain with the Seller, limiting INVO's exposure to pre-acquisition financial obligations.

Next Steps

• Closing of the acquisition, expected by February 27, 2026.
• Execution of a PC asset purchase agreement between Fertility, P.A. (New PC) and Family Beginnings, P.C. (Seller) for clinical assets.
• Execution of a management services agreement between INVO Centers LLC (Buyer) and New PC.
• Execution of an employment agreement between New PC and Dr. James Donahue for a minimum of three years.
• Execution of a new lease agreement between INVO Centers LLC (Buyer) and Landlord for the clinic property.
• Integration of Family Beginnings' operations into INVO Fertility.
• Expansion of the practice within the local market.

Key Dates

Recommendation

The acquisition of Family Beginnings is a strategic and accretive move for INVO Fertility, aligning with its stated mission to expand access to fertility care and grow its clinic network. The target clinic is profitable, and the retention of Dr. Donahue ensures continuity and leverages existing clinical expertise and patient relationships. The deal structure, including preferred stock, is prudent for capital management. While integration risks exist, the overall expansion into a new, established market with a reputable practice is a strong positive for INVO's long-term growth trajectory in the growing ART market.

Keywords

INVO Fertility, Family Beginnings, Fertility Clinic Acquisition, IVF, INVOcell, Assisted Reproductive Technology, Healthcare Services, Indiana, Mergers and Acquisitions, SEC Filing, 8-K